Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Agilent; Genetic Technologies; Horizon Discovery, Fox Chase Cancer Center; GeneNews

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies this week said that the United States-Latin American Cancer Research Network (US-LACRN) will use its microarray tools and associated products for a study of breast cancer in five Latin American nations. US-LACRN is a collaboration between the US' National Cancer Institute and the ministries of health in Mexico, Brazil, Argentina, Chile, and Uruguay.

Genetic Technologies Ltd. said that it has executed a preliminary research agreement with an unnamed pharmaceutical company to develop a new cancer profiling product. The Australian firm said that it will use its technologies to develop specific genetic oncology profiling systems for targeting chemotherapy in late-stage cancer patients.

Horizon Discovery this week said that it has inked a three-year collaborative agreement with the Fox Chase Cancer Center to apply its rAAV gene targeting in mouse embryonic stem cells and for the discovery of genes involved in resistance to EGFR-targeted therapies in human cancer. Horizon expects to develop new human isogenic disease models under the alliance and knock-out mouse models that will be exclusively licensed by Fox Chase in exchange for future product royalties.

GeneNews will undertake an early warrant exercise incentive program designed to encourage the exercise of up to 17.2 million common share purchase warrants of the firm prior to their expiry dates. The program will last for 22 days and begin on May 17. Each warrant exercised will entitle the exercising holder to receive one common share of GeneNews and one common share purchase warrant . Each whole incentive warrant will entitle the holder to purchase one common share at a price of C$0.25 (US$.26) until July 31, 2012. According to GeneNews, if all warrants eligible to participate in the program are exercised early, the firm would receive gross proceeds of up to C$4.1 million.